Martingale Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Martingale Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$146K	Buy	+10,163	New	+$113K	﹤0.01%	822
2022 Q3	–	Sell	-75,622	Closed	-$338K	–	908
2022 Q2	$338K	Buy	75,622 +10	+0%	+$46	0.01%	721
2022 Q1	$381K	Buy	75,612 +12,412	+20%	+$79K	0.01%	688
2021 Q4	$551K	Buy	63,200 +313	+0.5%	+$2.79K	0.01%	629
2021 Q3	$587K	Buy	62,887 +42,461	+208%	+$428K	0.01%	634
2021 Q2	$262K	Buy	+20,426	New	+$220K	﹤0.01%	743

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Martingale Asset Management's ZVRA Position: Q2 2026 in Review

Martingale Asset Management opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 10,163 shares worth $146K. The stake represents ﹤0.01% of the portfolio and ranks #822 among its holdings. This is a return to the name: Martingale Asset Management previously reported a position in ZVRA as recently as Q2 2022.

Martingale Asset Management first reported a position in ZVRA in Q2 2021 and has held it in 6 quarters since. The position peaked at $587K in Q3 2021. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Martingale Asset Management held 10,163 shares of Zevra Therapeutics worth $146K as of Q2 2026.
Zevra Therapeutics was a new Martingale Asset Management position in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of Martingale Asset Management's portfolio in Q2 2026, its #822 holding.
Martingale Asset Management first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 6 quarters since.
Martingale Asset Management's Zevra Therapeutics position peaked at $587K in Q3 2021.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.